Up and running again

A Boston Scientific therapy helped Esther overcome cancer pain.

Read her story

Featured stories
More than half of people in the U.S. diagnosed with colorectal cancer will see their cancer spread to their liver. Hepatic Artery Infusion (HAI) therapy can help.
May 1, 2026
What is colorectal cancer, and how is it treated?

Learn the symptoms of colorectal cancer and how it is treated, including options for colorectal cancer liver metastases.

Q1 2026 earnings highlights
Apr 22, 2026
Interested in our Q1 2026 earnings?

Get some key highlights of our performance this quarter.

The Nalu Neurostimulation System includes a miniaturized, battery-free implant that interrupts pain signals from going to the brain.
Mar 19, 2026
Four things to know about our acquisition of Nalu Medical

Learn how Boston Scientific’s acquisition of Nalu Medical expands treatment options for chronic peripheral nerve pain.

Read more stories

Press releases
May 19, 2026
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH,...

May 18, 2026
Boston Scientific enters into $2 billion accelerated share repurchase agreement

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion...

May 18, 2026
Boston Scientific announces strategic investment in MiRus LLC

Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston...

Read more press releases

In the news
Mar 29, 2026
Data supports Boston Scientific Watchman FLX™ in stroke reduction
MassDevice
The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.
Mar 28, 2026
HI-PEITHO kicks off ‘golden era’ in pulmonary embolism
MedPage Today
Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.
Jan 26, 2026
Hospitals are embracing pulsed field ablation. Here’s why
Modern Healthcare
Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.
Jan 15, 2026
Lab profile: Boston Scientific’s Arbor Lakes campus was built to be reconfigurable
R&D World
Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Read more news

2025 Impact Reporting

Advancing science for more innovative care, empowered people and a more sustainable future.

Learn about our impact

News alerts

Sign up to receive our press releases via email

Media contacts

Business and enterprise contacts for journalists

Media resources

Imagery and other resources

Top